IDR Data
CMS PUF data · 2023 Q1–2025 Q4

Federal IDR outcomes: Hospitals and facilities in Colorado

In 2025 Q1–Q4, the provider or facility offer prevailed in 43.5% of 4,745 determined Federal IDR dispute line items for hospitals and facilities in Colorado. The median prevailing offer was 1.00x the QPA (25th–75th percentile 0.37x–1.00x; n = 4,698). The median time to a decision was 93 business days (n = 4,745).

Determined line items

4,745

2025 Q1–Q4 · 8 split decisions excluded

Provider win rate

43.5%

n = 4,745 · 2025 Q1–Q4

Median payment vs QPA

1.00x

middle half 0.37x–1.00x · n = 4,698 · 2025 Q1–Q4

Median days to decision

93

business days, from dispute initiation · n = 4,745 · 2025 Q1–Q4

Dollar amounts are not shown for specialty groups: the CMS QPA and Offers file, the only source of dollar figures, has no specialty field. See methodology.

By period

PeriodLine itemsWin %Median ×QPA25th–75thRatio nMedian days
2025 Q1–Q44,74543.5%1.00x0.37x–1.00x4,69893
2024 Q1–Q460749.3%1.00x1.00x–1.00x59848
2023 Q1–Q4Fewer than 30 determined line items; not shown.
2023 Q1–2025 Q45,35744.2%1.00x0.45x–1.00x5,301not pooled

Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.

Most disputed CPT codes

CPT codeLine itemsWin %Median ×QPARatio nMedian days
99285 Emergency department visit with high level of medical decision making27843.2%1.00x27679.5
85025 Complete blood cell count (red cells, white blood cell, platelets), automated te26842.9%1.00x26398.5
80053 Blood test, comprehensive group of blood chemicals23744.7%1.00x23397
96374 Injection of drug or substance into vein15744.6%1.00x15491
93005 Routine electrocardiogram (ECG) using at least 12 leads with tracing15441.6%1.00x152111.5
96361 Infusion into a vein for hydration, each additional hour15449.4%1.00x15187.5
96375 Injection of additional new drug or substance into vein14749.0%1.00x14479
84484 Troponin (protein) analysis, quantitative14232.4%1.00x142104.5
74177 CT scan of abdomen and pelvis with contrast9452.1%1.00x9477.5
99284 Emergency department visit with moderate level of medical decision making8432.1%1.00x83133.5
71045 X-ray of chest, 1 view7245.8%1.00x70130
70450 CT scan head or brain without contrast6942.0%1.00x67119
84703 Gonadotropin (reproductive hormone) analysis6952.2%1.00x6883
83690 Lipase (fat enzyme) level6243.5%1.00x6179
83605 Lactic acid level6050.0%1.00x5984.5
81003 Automated urinalysis test5635.7%1.00x5576.5
96376 Injection of additional drug or substance into vein provided in a facility5145.1%1.00x50101
71275 CT scan of blood vessels of chest with contrast4725.5%1.00x4777
99291 Critical care, first 30-74 minutes4634.8%1.00x46116.5
82077 Measurement of alcohol level in specimen other than breath or urine4447.7%1.00x4487.5

2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.

Related: all specialties in Colorado · Hospitals and facilities in all states

FAQ

What is the Federal IDR provider win rate for hospitals and facilities in Colorado?

In 2025 Q1–Q4, the provider or facility offer was selected in 43.5% of 4,745 determined dispute line items for hospitals and facilities in Colorado. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.

How do Federal IDR payments compare with the QPA for hospitals and facilities in Colorado?

In 2025 Q1–Q4, the median prevailing offer was 1.00x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 0.37x to 1.00x (n = 4,698 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.

How long do Federal IDR decisions take for hospitals and facilities in Colorado?

In 2025 Q1–Q4, the median was 93 business days (n = 4,745 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).

How to Utilize IDR